Ed Kong

I'm honored to have worked on this project with my wonderful mentors and co-authors Ryan Sullivan, Hensin Tsao, and @DrStevenTChen.

These findings suggest that while novel therapies have transformed melanoma outcomes, a meaningful share of their potential benefit remains unrealized, particularly outside larger counties. Further work is needed to maximize the benefits of important new treatments.

I’m excited to share a new paper in JAAD on novel therapies in melanoma 🧵 We show melanoma mortality fell by ~26% following the introduction of immunotherapy and targeted therapies. authors.elsevier.com/a/1msKLhQtRfN%…

💻A simulation model in @JAMADerm shows the greatest QOL gains are linked with biologic therapies for #psoriasis. 💡Home phototherapy offers ⬇️ cost for patients & payers, yet remains underused. @GoHealio spoke with @edkong of @harvardmed to learn more. vist.ly/4vfi5

🚨 What happens when the gov't cuts prices on medical technologies? New research (w/ @YunanJi) finds a 61% price cut led to: 75% drop in innovation (may fully offset savings) 49% fewer new firms 28% more production moved overseas 3x repair/replacement rate 🧵(1/n)

Truly an honor to have had the chance to write this paper with @AMostaghimi

Not too much goin' on today, so I thought I'd tell you about a new paper just published in @NEJMEvidence, w/ @metrics52, @carolxmgao, and @rwyeh We explain why instrumental variable (IV) methods are essential for randomized trials of medical interventions that fail to play out as intended (i.e., with imperfect treatment takeup & control group crossover) In an application to the landmark ISCHEMIA trial, these methods show that the benefits of revascularization on quality of life are 46% higher than what a conventional "intentions-based" analysis would suggest Check it out! dropbox.com/scl/fi/lsnmm2g…

What a time to be alive

Office space for 2 grad students

The best study I know estimates that each dollar of NIH spending generates $1.40-$2.80 in value counting *only the private return from drugs*, ignoring consumer surplus, med devices, public health, behavioral science, etc...

Why we can’t defund science

Every synthetic biologist, every biochemist, when they dream, will sometimes hear a voice calling A whisper on the wind, as impossible as infinity, as sweet as the ambrosia of the very Gods "Engineer RuBisCo" And this paper takes us one step closer nature.com/articles/s4158…

Finished the blog post, link below